1

1 The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection is Linked 2 to the Presence of Long COVID Symptoms

3 4

Short Title: Antibody Breadth and Long COVID

5 6 **AUTHORS**

- Amanda M. Buck^{1*}, Amelia N. Deitchman^{6*}, Saki Takahashi², Scott Lu³, Sarah A. Goldberg³, Rebecca 7
- Hoh², Meghann C. Williams², Marian Kerbleski², Tyler-Marie Deveau¹, Sadie E. Munter¹, James 8
- Lombardo², Terri Wrin⁴, Christos J. Petropoulos⁴, Matthew S. Durstenfeld⁵, Priscilla Y. Hsue⁵, J. Daniel 9
- Kelly³, Bryan Greenhouse², Jeffrey N. Martin³, Steven G. Deeks², Michael J. Peluso^{2*}, Timothy J. 10 Henrich^{1*^}
- 11
- 12
- 13 ¹ Division of Experimental Medicine, University of California San Francisco, San Francisco, CA, United 14 States
- 15 ² Division of HIV, ID and Global Medicine, University of California San Francisco, San Francisco, CA,
- 16 **United States**
- 17 ³ Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco,
- 18 CA, United States
- 19 ⁴ Monogram Biosciences, South San Francisco, CA, United States
- 20 ⁵ Division of Cardiology, University of California San Francisco, San Francisco, CA, United States
- 21 ⁶ Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA, United 22 States
- 23
- 24 *contributed equally, ^co-corresponding author
- 25
- 26 Corresponding Authors:
- 27 Michael J. Peluso
- 28 michael.peluso@ucsf.edu
- 29 Division of HIV, Infectious Diseases, and Global Medicine
- University of California San Francisco 30
- 31 1001 Potrero Ave
- 32 San Francisco, CA 94110
- 33
- 34 Timothy J. Henrich
- 35 timothy.henrich@ucsf.edu
- **Division of Experimental Medicine** 36
- 37 University of California San Francisco
- 1001 Potrero Ave 38
- 39 San Francisco, CA 94110
- 40
- 41
- 42
- 43 Summary: SARS-CoV-2-specific antibody neutralization of Omicron BA.5 variant approximately 4
- 44 months following acute infection with wild-type virus prior to vaccination was independently and
- 45 significantly associated with greater odds of distinct Long COVID phenotypes.

2

46 ABSTRACT

47 Background: The associations between longitudinal dynamics and the breadth of SARS-CoV-2
48 neutralizing antibody response with various Long COVID (LC) phenotypes prior to vaccination are not
49 known. The capacity of antibodies to cross neutralize a variety of viral variants may be associated with
50 ongoing pathology and persistent symptoms.

51 **Methods:** We measured longitudinal neutralizing and cross-neutralizing antibody responses to pre- and 52 post-SARS-CoV-2 Omicron variants in participants infected during the early waves of the COVID-19 53 pandemic, prior to wide-spread rollout of SARS-CoV-2 vaccines. Cross sectional regression models 54 adjusted for various clinical covariates and longitudinal mixed effects models were used to determine 55 the impact of the breadth and rate of decay of neutralizing responses on the development of Long 56 COVID symptoms in general, as well as LC phenotypes.

57 Results: We identified several novel relationships between SARS-CoV-2 antibody neutralization and 58 the presence of LC symptoms. Specifically, we show that, although neutralizing antibody responses to 59 the original, infecting strain of SARS-CoV-2 were not associated with LC in cross-sectional analyses, 60 cross-neutralization ID50 levels to the Omicron BA.5 variant approximately 4 months following acute 61 infection was independently and significantly associated with greater odds of LC and with persistent 62 gastrointestinal and neurological symptoms. Longitudinal modeling demonstrated significant 63 associations in the overall levels and rates of decay of neutralization capacity with LC phenotypes. A 64 higher proportion of participants had antibodies capable of neutralizing Omicron BA.5 compared with 65 BA.1 or XBB.1.5 variants.

66 Conclusions: Our findings suggest that relationships between various immune responses and LC are
67 likely complex but may involve the breadth of antibody neutralization responses.

Keywords: COVID-19, SARS-CoV-2; Neutralizing Antibodies; Long COVID; Post-Acute Sequelae of
 SARS-CoV-2 infection (PASC)

3

70 INTRODUCTION

71 Many individuals experience post-acute sequelae of SARS-CoV-2 infection (PASC), which can affect 72 quality of life and return to health [1-3]. The etiologic drivers of Long COVID (LC), a form of PASC 73 defined by ongoing, often debilitating, symptoms, are poorly understood and likely involve multiple 74 mechanisms [2, 4, 5]. Proposed mechanisms include aberrant autoreactive immune responses, 75 microvascular dysregulation, and reactivation of latent human herpesviruses which may lead to the 76 systemic inflammatory responses now identified in individuals with Long COVID compared to those 77 who fully recovered [6-11]. Furthermore, there is arowing evidence that SARS-CoV-2 subgenomic RNA 78 and proteins are present in the tissues of at least a subset of immunocompetent individuals with LC [12-79 14]. Although those with persistent symptoms tend to have higher levels of SARS-CoV-2 Spike-specific 80 antibody levels [10, 15-18], we and others have previously demonstrated that LC is associated with 81 adaptive immune dysregulation and exhaustion [15, 18].

SARS-CoV-2 infection leads to rapid development of robust antibody responses, although neutralizing capacity wanes more quickly than total Spike IgG levels over time [17, 19-21]. A higher initial viral burden or persistence of viral antigens may lead to observed dysregulated immune phenotypes and higher antibody levels. However, there is a paucity of information regarding the associations between longitudinal dynamics or the breadth of the neutralizing antibody response with various LC phenotypes with some data showing that weaker antibody responses over time being associated with LC [22].

Recent pre-print data suggests that an expanded antibody response against the prior OC43 endemic coronavirus may be associated with Long COVID [23]. This suggests that the breadth of the response to initial infection may play an important role in the development of LC. Given that the rapid emergence of Omicron variants that evade neutralization result from infection from older SARS-CoV-2 strains (*e.g.*, ancestral SARS-CoV-2, Alpha and Delta variants) as well as to COVID-19 vaccines [24, 25], there is strong interest in determining the relationship between the breadth and durability of the initial antibody responses and the presence of Long COVID symptoms. The rapid emergence of novel variants and

4

95 increased incidence of reinfection also necessitates studies of longitudinal antibody responses following
96 COVID-19 [26].

- 97 Here, we measured longitudinal neutralizing antibody responses to pre-Omicron strains and to
- 98 subsequent Omicron variants in participants infected during the early waves of the COVID-19
- 99 pandemic, prior to their receiving SARS-CoV-2 vaccines. Cross sectional regression models adjusted
- 100 for various clinical covariates and longitudinal mixed effects models were used to determine the impact
- 101 of the breadth and rate of decay of neutralizing responses on the development of Long COVID
- symptoms in general, as well as distinct Long COVID symptom phenotypes.
- 103

104 METHODS

105 Clinical Cohort and Sample Collection. Participants were enrolled in the University of California, San 106 Francisco (UCSF)-based Long-term Impact of Infection with Novel Coronavirus (LIINC) COVID-19 107 study (NCT04362150). The cohort design and procedures have been described in detail elsewhere [4]. 108 Briefly, at each visit participants complete an interviewer-administered questionnaire querying the 109 presence in the preceding 2 days of symptoms that are new since COVID-19 or worsened from pre-110 COVID baseline, prior to the collection of peripheral blood. This analysis included longitudinal 111 measurements from 184 participants, including plasma samples collected between 1 and 4 months 112 after initial symptom onset. All samples were collected prior to the participant having received any 113 SARS-CoV-2 vaccination and a large majority were collected during the original SARS-CoV-2 wave 114 (timing of sample collections here- maybe first and last date of collection), all prior to Omicron variant 115 emergence. Phenotypic clusters were based on 32 participant-reported symptoms as previously 116 described [4].

PhenoSense SARS CoV-2 nAb Assay. The measurement of nAb activity using the PhenoSense
 SARS CoV-2 nAb Assay (Monogram Biosciences, South San Francisco, CA) was performed by

5

119 generating HIV-1 pseudovirions that express the SARS CoV-2 Spike protein as previously described 120 [20, 27-29]. The pseudovirus is prepared by co-transfecting HEK293 producer cells with an HIV-1 121 genomic vector that contains a firefly luciferase reporter gene together with a SARS CoV-2 Spike 122 protein expression vector. Neutralizing antibody activity is measured by assessing the inhibition of 123 luciferase activity in HEK293 target cells expressing the ACE2 receptor and TMPRSS2 protease 124 following pre-incubation of the pseudovirions with serial dilutions of the serum specimen. ID50 values 125 was generated for the original SARS-CoV-2 Spike protein as well as the following variants: Alpha 126 (B.1.1.7), D614G mutant, Delta (B.1.617.2), Omicron BA.1 (B.1.1.529), Omicron BA.5 (B.1.1.529). A 127 subset of samples stratified by negative or ID50s to the BA.5 strain were performed in an expanded pool consisting of pseudoviruses incorporating spike proteins from BA.2, BA.4.6, XBB.1.5 and BQ.1.1. 128 129 Statistical analyses. Antibody data were generated blinded to participant information. Comparisons of 130 ID50 values across comparator groups incorporated non-parametric Mann-Whitney or Freidman tests 131 with Dunn correction for multiple comparisons using Prism v. 8 (GraphPad Software) and SPSS v. 29 132 (IBM). Adjusted P values reported in analyses involving multiple comparisons. For tabular data, two-133 tailed Fisher's exact testing was performed on categorical data and two-tailed, non-parametric Mann-134 Whitney testing was performed on continuous variables (SPSS v. 29). Spearman Rank Correlation 135 analysis was used to compare T cell, antibody and soluble markers of inflammation (Prism v. 8). For 136 longitudinal analyses, linear mixed effects modeling was performed for neutralizing antibody ID50 (log 137 transformed) in R (version 4.0.2) using Ime4 package (version 1.1) with time and individual factors 138 (e.g., age, sex, COVID-19 hospitalization, prior history of diabetes, prior autoimmune disease, body 139 mass index >30, Long COVID symptoms) as predictors, and random effects based on participant. 140 Spearman's correlation was performed in R to test for relationships between variant neutralizing 141 antibody ID50 across all time points. Logistic regression models were performed on cross sectional 142 data including the constant to identify independent associations between model factors and Long 143 COVID outcomes using SPSS v. 29. Models included various demographic variables as well as either

6

Log-transformed ID50 values or binary categorical indicators of ID50 values above a specific threshold
as determined by sensitivity analyses.

146 **Study approval.** All participants provided signed written informed consent prior to participation. The

147 UCSF IRB approved the study.

- 148
- 149 **RESULTS**

150 **Clinical cohort and participant demographics.** To evaluate neutralizing responses in participants 151 with prior COVID-19 and to assess relationships between these responses and the presence of Long 152 COVID symptoms, we analyzed plasma samples collected from 184 participants with and without Long 153 COVID symptoms across 384 timepoints for up to 4 months following acute infection. Participants had a 154 median of 2 sample time points across all visits (ranging from 1 to 4). In general, participant visits 155 occurred approximately 1 month, 2 months or 4 months following nucleic acid-confirmed SARS-CoV-2 infection. All specimens and symptom reports were timed from the day of initial COVD-19 symptom 156 157 onset.

158 All participants were initially infected prior to emergence of the Delta strain (last date of infection was in 159 March of 2021) and all but 7 samples across all time points were collected prior to the end of February 160 2021 (the time of vaccine availability to the general public in the Unites States). Long COVID was 161 defined broadly as the presence of any symptom new or worsened since acute SARS-CoV-2 infection 162 not clearly attributable to another cause. Table 1 shows the clinical and demographic factors of 163 participants grouped by the presence or absence of any Long COVID symptom. The group with Long 164 COVID was enriched for women (58.4% vs 39.4%, P<0.05), those who had been hospitalized during 165 acute COVID-19 (24.8% vs 19.7%, not significant), those with a history of pre-existing autoimmune 166 disease (mainly thyroiditis, 10.6% vs 1.4%, P<0.05), persons self-reporting Latinx ethnicity (34.5% vs 167 19.7%, P<0.05), and those with higher body mass index (27.7 vs 26.0 kg/m², P<0.05) (**Table 1**).

7

168 Breadth of antibody neutralization to the original infecting SARS-CoV-2 variant and subsequent

viral variants. Using the PhenoSense assay (Monogram Biosciences), we measured the inhibitory

170 serum dilutions at which 50% neutralization occurred (ID50) using pseudoviruses expressing SARS-

- 171 CoV-2 Spike protein from the original strain (with which a majority of our participants were infected) and
- the following subsequent variants: Alpha (B.1.1.7), D614G mutant, Delta (B.1.617.2), Omicron BA.1

173 (B.1.1.529), and Omicron BA.5 (B.1.1.529). Overall, neutralization levels were highly variable between

- 174 participants. Antibody neutralization responses were consistently highest to the original, infecting
- 175 SARS-CoV-2 strain along with the Alpha, Beta, and Delta variants, with levels declining between 1 and
- 176 4 months following acute infection (Figure 1A-C). Although very low levels of cross-neutralization were
- 177 observed with the Omicron BA.1 variant, a higher proportion of participants had antibodies able to
- 178 neutralize Omicron BA.5 up to four months following initial presentation (the last study time point).
- Across all time points, 12.5% of neutralizing titers were below the level of assay positivity to the original
- 180 SARS-CoV-2 pseudovirus and 78.4% and 67.4% below the level of positivity for the BA.1 and BA.5
- 181 variant, respectively. Correlations of neutralization capacity to each SARS-CoV-2 variant are shown in
- 182 Supplementary Figure 1.

169

183 We tested a subset of 16 participants including samples chosen with either high or low Omicron BA.5 184 responses across all timepoints on an expanded panel of Omicron sub variants to better understand 185 the full breadth of cross-neutralization responses between ancestral and recent or current circulating 186 strains as shown in Figure 1D. The expanded neutralization panel included BA.4.6, BQ.1.1 and 187 XBB.1.5. Similar neutralization titers were observed between BA.5, BA.4.6, and BQ1.1, whereas 188 XBB.1.5 responses most closely resembled BA.1 responses, which were overall low or negative across 189 participants. BA.2 responses were more evenly distributed across a range of neutralization ID50s 190 compared to the other Omicron sub variants.

Decay of variant-specific SARS-CoV-2 antibody neutralization by clinical phenotype. Leveraging
 mixed effects modeling approaches, we analyzed neutralizing responses over time by clinical and

8

193 demographic characteristics, including age, sex, hospitalization during acute infection, body mass index 194 (BMI), and a pre-existing history of diabetes mellitus for the most clinically relevant variants in our study 195 population (ancestral SARS-CoV-2, Delta and Omicron sub variants; Figure 2). Overall, antibody 196 neutralization ID50 decreased over time for all strains (p<0.01) with the exception of the Omicron BA.1 197 variant, (p=0.16) for which initial levels were substantially lower than to the other variants. When 198 stratifying by age greater than 50 years, we identified no difference in antibody neutralization to all 199 variants tested across all time points in the mixed effects models. In contrast, male sex was associated 200 with higher viral neutralization for original SARS-CoV-2, Delta, and Omicron BA.5 variants, but not for 201 Omicron BA.1, across all time points. These observed sex-based differences were similar between 202 original and Delta variants, each approximately 0.41 and 0.33 log₁₀ higher, respectively, observed in 203 males compared to females recovering from COVID-19.

204 For those hospitalized during acute infection, neutralization levels were significantly higher across all 205 strains with the exception of BA.1. The magnitude of the difference in responses for those hospitalized 206 versus not hospitalized was diminished with those strains with lower overall responses: 1.18 and 0.94 207 log₁₀ higher responses for the original virus and Delta variant versus 0.33 and 0.28 log₁₀ higher for 208 omicron BA.1 and BA.5 responses, respectively. Individuals with pre-existing diabetes also had 209 differential neutralization across variants, with higher initial levels and longitudinal levels over all time 210 points, and showing a more rapid decline over time compared to those without diabetes. The 211 magnitude of wild-type SARS-CoV-2 responses for those with a BMI >30 was higher across all time 212 points for the original and delta viral strains (All P<0.001) and declined more rapidly for the original 213 Delta and Omicron BA.5 variants (All P>.012; Supplemental Figure 2). In contrast, neutralization 214 ID50s from participants with a pre-existing history of diabetes mellitus were overall lower across all time 215 points for the original SARS-CoV-2 (All P <0.05) and ID50s to the original strain and Delta variant 216 declined less rapidly (P<0.05).

9

Breadth of the neutralizing antibody responses is associated with increased odds of Long COVID. In order to determine whether neutralization capacity was related to Long COVID, we

219 performed logistic regression modeling with either the presence of any Long COVID symptom at a 220 given sample time point or with specific Long COVID symptom phenotype (neurocognitive, 221 cardiopulmonary, gastrointestinal, musculoskeletal and fatigue) at the three main collection time points: 222 1 month (N=69; median 33 days), 2 months (N=115; median 59 days) and 4 months (N=119; median 223 120 days) following acute infection. Data from only one time point per participant within each time 224 period was included to avoid oversampling of specific individuals. Specifically, the sample time closest 225 to 30 days within a 21-45 day window, 60 days within a 56-75 day window, and 120 days within a 100-226 150 day window were included. Factors included in the first model (Figure 3A) included the neutralizing 227 antibody ID50 (continuous variable), prior hospitalization during acute COVID-19, female sex, and age 228 greater than 50 years of age. Overall, there were no significant differences between neutralization ID50 229 to any strain and the presence of Long COVID in general or any specific Long COVID phenotype at 1 230 and 2 months following acute infection (all P>0.05). As shown in Figure 3A, the neutralization ID50 of 231 the ancestral SARS-CoV-2 (the infecting strain in this study population), as well as Alpha and Delta 232 variants, were not significantly associated with the presence of any Long COVID symptom or specific 233 Long COVID phenotype approximately 4 months after acute infection. However, cross-neutralization 234 ID50s to Omicron BA.5 were significantly and positively associated with neurocognitive and 235 gastrointestinal symptoms (*i.e.* higher odds of having symptoms within these phenotypes). There were 236 no significant associations between BA.5 neutralization ID50 and fatigue and cardiopulmonary 237 symptoms or as shown in **Supplementary Figure 3**). Regression analyses including ID50s to both 238 wild-type SARS-CoV-2 and Omicron BA.3 were also performed as in Supplementary Figure 4A. 239 Including ID50s to both wild type and BA.5 strains led to similar results, with cross-neutralization to 240 Omicron BA.5 being significantly associated with having any Long COVID symptom and neurocognitive 241 symptoms, whereas ancestral SARS-CoV-2 ID50 were not significantly associated with Long COVID or 242 any symptoms cluster.

10

Female sex was positively and significantly associated with an increased odds of Long COVID in models including both the original infecting virus and cross-neutralization to the Omicron BA.5 variant. Hospitalization for acute COVID-19 was only significantly associated with Long COVID in the model incorporating the original SARS-CoV-2 strain pseudovirus. A pre-existing history of diabetes mellitus or autoimmune disease were included in subsequent regression models but were not significantly associated with Long COVID outcomes and did not influence significance of other factors.

249 To further test the relationship between cross-neutralization of BA.5 pseudoviruses with the

250 development of Long COVID symptoms, we performed binary logistic regression including only the top

251 15% of neutralization ID50s in both the original SARS-CoV-2 and BA.5 variant based on results from a

sensitivity analysis to evaluate the influence of the samples with robust cross-neutralization of BA.5 as

shown in **Figure 3B**. Consistent with the above analyses, there were no significant associations

between the top neutralization responders to the original virus and PASC or PASC phenotype, whereas

255 presence of robust cross-neutralization to Omicron BA.5 was significantly associated with a higher odds

of any PASC symptom and neurocognitive and gastrointestinal PASC phenotypes. We repeated

regression analysis with ancestral wild-type and Omicraon BA.5 in the same model and results were

similar with high cross-neutralization to BA.5 being significantly associated with any Long COVID

symptom and neurocognitive and gastrointestinal symptoms clusters (Supplementary Figure 4B).

260 Decay of SARS-CoV-2-specific antibody neutralization over time by Long COVID phenotype.

Finally, we assessed neutralizing antibody responses against the original infecting SARS-CoV-2 strain by individual Long COVID phenotype (*i.e.* non mutually exclusive symptom cluster) compared to those without any Long COVID symptoms or those with or without symptoms but not within the specific Long COVID symptom cluster (**Figure 4A & B**, respectively). Overall, differences in levels across all time points or changes over time were similar, with high interpatient variation in neutralization ID50s observed. Nonetheless, we found that those with gastrointestinal and cardiopulmonary symptoms had 0.27 and 0.43 log₁₀ higher neutralization ID50 compared to those without any Long COVID symptom

11

268 across all data points over time (P=0.04 and <0.001, respectively; Figure 4A). Decay in neutralization ID50 was faster (i.e. more negative slope in mixed linear effects model) in participants with 269 270 cardiopulmonary and musculoskeletal symptoms compared to those without any symptoms (P=0.01 271 and 0.047, respectively). Compared to those with or without persistent symptoms, but no symptoms in 272 the specified phenotype cluster, those with cardiopulmonary or musculoskeletal symptoms were overall 273 higher across all time points (both P<0.001), and those with musculoskeletal, cardiopulmonary and 274 neurocognitive symptoms declined more rapidly than those without those specific symptoms (all P < 275 0.05; Figure 4B).

276

277 DISCUSSION

278 In this longitudinal study of a well-characterized cohort of people recovering from COVID-19 during the 279 early waves of the pandemic prior to emergence of Delta and subsequent variants and availability of 280 vaccines, we identified several novel relationships between SARS-CoV-2 antibody neutralization and 281 the presence of Long COVID symptoms. First, we show that, although neutralizing antibody responses 282 to the original, infecting strain of SARS-CoV-2 were not associated with Long COVID in cross-sectional 283 analyses, cross-neutralization ID50 levels to the Omicron BA.5 variant approximately 4 months 284 following acute infection were independently and significantly associated with greater odds of Long 285 COVID in general and specifically with persistent gastrointestinal and neurological symptoms. These 286 data suggest that a broad antibody response to subsequent viral variants may predict emergence of 287 various LC symptoms. Supporting this finding, a recent preprint suggested that people with LC may 288 have an expanded antibody response against the prior OC43 endemic Coronavirus [23]. The 289 researchers also demonstrated more avid IgM responses and inflammatory OC43 S2-specific Fc-290 receptor binding responses but weaker Fc-receptor binding to SARS-CoV-2 [23]. Whether or not the 291 association between breadth of response and LC is due to or related to processes such as autoreactive 292 antibody formation warrants further investigation.

12

293 Interestingly, we observed that a higher proportion of people infected early during the pandemic had antibodies capable of neutralizing Omicron BA.5 compared with BA.1, to which very few participants 294 295 demonstrated any cross-neutralization response. The reason for this is not known, but several amino 296 acid mutations in the receptor binding domain (RBD) of SARS-CoV-2 Spike protein in the BA.1 strain 297 reverted to wild-type in the BA.5, such as G446S, Q493R and G496R [19, 30]. The BA.5 variant also 298 had reversion of amino acid mutations or insertions in non RBD areas of Spike to pre BA.1 variants 299 (e.g. L981F, ins214EPE, T95I) [19, 30]. In the sub-analysis of samples from 16 participants stratified by 300 the highest and lowest BA.5 neutralization titers, we also observed consistently higher cross-301 neutralization with BA.2, BA.4.6 and BQ.1.1 sub variants. In contrast, lower neutralization ID50s to 302 XBB.1.5 pseudovirus were observed, similar to BA.1 neutralization. Whether or not there are any 303 clinical implications of increased cross-neutralization in those infected early in the pandemic with 304 subsequent Omicron variants is not known. It is also not clear if infection with Omicron strains leads to 305 increased or decreased risks of Long COVID, but it will be very difficult to identify variant-specific 306 effects in the current era of widespread and variable vaccination, reinfection, and antiviral treatment 307 uptake.

308 We also evaluated the longitudinal relationships between antibody neutralization responses, various 309 clinical factors, and Long COVID phenotypes. The mixed effects models allowed us to determine 310 differences between these variables across all data points over time (including multiple time points for 311 each individual) and changes (*i.e.* decay) over time. These analyses revealed relationships between 312 neutralization responses that were not observed in the cross-sectional analyses, such as significantly 313 higher SARS-CoV-2 neutralizing responses to the original infection SARS-CoV-2 across all time points 314 for those with gastrointestinal and cardiopulmonary Long COVID symptoms. Regardless of the overall 315 higher levels, a faster decay of neutralizing ID50 was observed for these phenotypic clusters, in 316 addition to those with musculoskeletal symptoms. Of note, neutralization titers decay more rapidly on a 317 whole than common epitope antibody responses which have been associated with various PASC

13

318 symptoms in longitudinal analyses [16, 17, 20], highlighting importance of temporal immune dynamics 319 in the study of this condition. Together, these and the cross-sectional data suggest that an overall 320 higher neutralization response that wanes more quickly, or ones that remain broad over time, are 321 associated with LC. While the causes of these dynamics are unknown, one possibility is that persistent 322 SARS-CoV-2 antigen presentation in tissues, which has been proposed as a potential mechanism of 323 Long COVID, may lead to overall higher antibody neutralization over time, and potentially to a broader 324 response to subsequent variants. While speculative, our findings suggest that relationships between 325 various immune responses and Long COVID are likely complex, and different approaches to data 326 analyses may yield different, but complementary information.

327 Strengths of this study include the use of highly characterized samples from the pre-vaccine and pre-328 Omicron era, before reinfections became common. This allowed for a more straightforward analysis of 329 neutralization dynamics in the absence of these complex confounding factors. In addition, both those 330 with and without Long COVID were recruited and assessed in an identical manner, addressing potential 331 biases that might occur when comparison groups are derived from different cohorts as has been 332 common in studies of Long COVID. As in similar analyses where we have been able to evaluate 333 mechanisms according to distinct Long COVID phenotypes [9], we leveraged our high degree of 334 symptom characterization to analyze different case definitions of Long COVID. This approach is 335 informative, especially since the case definition remains controversial and it is possible that different 336 phenotypes are driven by different mechanisms. Limitations of the study include a lack of participants 337 infected with more recent variants, preventing us from extending our observations into more recent 338 waves of the pandemic. The cohort was a convenience sample, and although this allows for valid 339 inferences regarding Long COVID biology comparing people with and without the phenotype of interest 340 within the cohort, extrapolation to all individuals with prior COVID-19 must be done cautiously. The 341 neutralization assay used Spike protein pseudoviruses rather than intact, replication-competent virus, 342 but these pseudovirus assays have been shown to have comparable results in several studies [27, 29,

14

343 31-33]. Nonetheless, we believe that these results suggest at least one potential contributor to Long

344 COVID, although more work will be necessary to validate these observations in other cohorts, including

those derived from later waves of the pandemic in the setting of vaccination or reinfection.

346 FOOTNOTES

347 <u>Funding sources</u> This work was supported by the NIH/National Institute of Allergy and Infectious

348 Diseases 3R01AI141003-03S1 (TJH), K23A137522 (MJP), and K23AI162249 (AND).

349 <u>Conflicts of Interest:</u> MJP reports consulting fees for Gilead Sciences and AstraZeneca, outside the 350 submitted work. TJH receives grant support from Merck and Co. and has consulted for Roche and

351 Regeneron.

352 <u>Acknowledgements</u>: We are grateful to the study participants and their medical providers. We

acknowledge current and former LIINC clinical study team members Tamara Abualhsan, Andrea

354 Alvarez, Khamal Anglin, Urania Argueta, Mireya Arreguin, Kofi Asare, Melissa Buitrago, Monika

355 Deswal, Nicole DelCastillo, Emily Fehrman, Halle Grebe, Heather Hartig, Yanel Hernandez, Beatrice

356 Huang, Raushun Kirtikar, Monica Lopez, Michael Luna, Lynn Ngo, Enrique Martinez Ortiz, Antonio

357 Rodriguez, Justin Romero, Dylan Ryder, Ruth Diaz Sanchez, Matthew So, Celina Chang Song, Viva

358 Tai, Alex Tang, Cassandra Thanh, Fatima Ticas, Leonel Torres, Brandon Tran, Daisy Valdivieso, and

359 Deepshika Varma; and LIINC laboratory team members Joanna Donatelli, Jill Hakim, Nikita Iyer, Owen

360 Janson, Brian LaFranchi, Christopher Nixon, Isaac Thomas, and Keirstinne Turcios. We thank Jessica

361 Chen, Aidan Donovan, Carrie Forman, and Rania Ibrahim for assistance with data entry and

362 review. We thank the UCSF AIDS Specimen Bank for processing specimens and maintaining the LIINC

363 biospecimen repository. We are grateful to Elnaz Eilkhani and Monika Deswal for regulatory support.

364 We are also grateful for the contributions of LIINC leadership team members: Isabelle Rodriguez-

365 Barraquer, and Rachel Rutishauser.

366

15

Table 1. Participant demographics, comorbidities, and clinical presentation in participants with

 and without post-acute sequelae of SARS-CoV-2 infection

	All Participants	No Long COVID	Long COVID ^a
Ν	184	71	113
Female Sex	94 (51.1%)	28 (39.4%)	66 (58.4%)*
Age (median, IQR)	44 (34, 53)	43 (33, 53)	45 (36, 54)
COVID-19 Hospitalization	42 (22.8%)	14 (19.7%)	28 (24.8%)
Pre-Existing Medical Condition			
Diabetes Mellitus	20 (10.9%)	11 (15.5%)	9 (8.0%)
Autoimmune Disease	13 (7.1%)	1 (1.4%)	12 (10.6%)*
Race/Ethnicity			
Latinx	53 (28.8%)	14 (19.7%)	39 (34.5%)*
White	100 (54.3%)	40 (56.3%)	60 (53.1%)
Black/African American	4 (2.2%)	3 (4.2%)	1 (0.9%)
Asian	22 (12.0%)	13 (18.3%)	9 (8.0%)
American Indian/Native Alaskan	1 (0.5%)	0 (0%)	1 (0.9%)
Pacific Islander/Native Hawaiian	3 (1.6%)	0 (0%)	3 (4.2%)
Body Mass Index ^b	26.7 (23.4, 31.2)	26.0 (23.1, 28.8)	27.7 (23.6, 32.9)*

COVID-19 = coronavirus disease 2019; IQR = interquartile range

^a Long COVID as defined as any persistent symptom new since COVID-19 onset at least 3 months following acute infection.

^b n = 178 excluding missing values

* P < 0.05 by two-sided Fisher's exact test for categorical data or by two-sided Mann-Whitney U test for continuous data.

368

369

16



378 subsequent viral variants. Ex vivo antibody neutralization of the original SARS-CoV-2 virus and 379 subsequent variants approximately 1 month (A, N=69), 2 months (B, N=115), and 4 months (C, N=119) following acute infection for all participants. Subgroup analysis of cross-neutralization in an expanded 380 381 Omicron sub variant panel (N=16) in a subset of participants that had samples across all timepoints 382 with either high or negative neutralization to BA.5 (D). Most samples collected prior to SARS-CoV-2 383 vaccination and prior to the emergence of Delta and Omicron variants. Bars represent mean antibody 384 (Ab) infectious dose 50% (ID50) values and 95% confidence intervals (* P<0.05, ** P<0.01, ***P<0.001 385 by two-sided Freidman test adjusted for multiple comparisons).

- 386
- 387
- 388



Figure 2. Longitudinal analysis of antibody neutralization by demographics, clinical factors and SARS CoV-2 variant. Mixed-linear regression model with four covariates (*i.e.* age, sex, hospitalization status, and prior
 diabetes history) for different variants: SARS-CoV-2, B.1.617.2, B.1.1.529 and BA.4/5. P-values denote if a
 significant difference was observed for change in antibody neutralization over time (Change over time), between
 subgroup (Phenotype, e.g., no diabetes versus diabetes), and difference in change over time by subgroup

394 (Change over time by phenotype, *e.g.* difference in slope of decline in antibody levels dependent on diabetes

versus no diabetes). Shaded region represents 95% confidence intervals around the median line.

18





- 410
- 411
- 412 Figure 4. Differential decay of SARS-CoV-2-specific neutralizing antibody responses among Long COVID 413
- Symptom Phenotypes. Longitudinal decay of antibody responses compared between participants with Long 414
- COVID Symptom Phenotype (e.g. musculoskeletal, gastrointestinal, cardiopulmonary, neurocognitive) a) versus
- 415 those without Long COVID (left panels) or b) versus those with other Long COVID Symptom Phenotypes (right
- 416 panels). Each panel includes p-values for: the decay across all participants ("change over time"), differences in
- 417 antibody neutralization for those with Long COVID phenotype across all timepoints (Symptom Phenotype), and
- 418 differences in change over time with a given Long COVID phenotype (Change over time by phenotype). Shaded
- 419 region represents 95% confidence intervals around the median line.

20

420 **REFERENCES**

- Ayoubkhani, D., et al., Trajectory of long covid symptoms after covid-19 vaccination: community
 based cohort study. BMJ, 2022. 377: p. e069676.
- Seessle, J., et al., Persistent Symptoms in Adult Patients 1 Year After Coronavirus Disease
 2019 (COVID-19): A Prospective Cohort Study. Clin Infect Dis, 2022. 74(7): p. 1191-1198.
- 426 3. Yang, C., et al., Omicron variants of SARS-CoV-2 and long COVID. Front Immunol, 2022. 13: p.
 427 1061686.
- Peluso, M.J., et al., Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality
 of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for
 Measurement. Open Forum Infect Dis, 2022. 9(2): p. ofab640.
- 431 5. Peluso, M.J., J. Donatelli, and T.J. Henrich, Long-term immunologic effects of SARS-CoV-2
 432 infection: leveraging translational research methodology to address emerging questions. Transl
 433 Res, 2021.
- 434 6. Peluso, M.J. and S.G. Deeks, Early clues regarding the pathogenesis of long-COVID. Trends
 435 Immunol, 2022. 43(4): p. 268-270.
- 436 7. Mehandru, S. and M. Merad, Pathological sequelae of long-haul COVID. Nat Immunol, 2022.
 437 23(2): p. 194-202.
- 438 8. Castanares-Zapatero, D., et al., Pathophysiology and mechanism of long COVID: a
 439 comprehensive review. Ann Med, 2022. 54(1): p. 1473-1487.
- Peluso, M.J., et al., Chronic viral coinfections differentially affect the likelihood of developing
 long COVID. J Clin Invest, 2023. 133(3).
- Su, Y., et al., Multiple early factors anticipate post-acute COVID-19 sequelae. Cell, 2022.
 185(5): p. 881-895 e20.
- 444 11. Gold, J.E., et al., Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr
 445 Virus Reactivation. Pathogens, 2021. 10(6).
- Swank, Z., et al., Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2
 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. Clin Infect Dis, 2023.
 76(3): p. e487-e490.
- 13. Natarajan, A., et al., Gastrointestinal symptoms and fecal shedding of SARS-CoV-2 RNA
 suggest prolonged gastrointestinal infection. Med (N Y), 2022. 3(6): p. 371-387 e9.
- 451 14. Peluso, M.J., et al., SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of
 452 COVID-19. Ann Neurol, 2022. 91(6): p. 772-781.

21

453	15.	Klein, J., et al., Distinguishing features of Long COVID identified through immune profiling.
454		medRxiv, 2022.
455	16.	Fjelltveit, E.B., et al., Symptom Burden and Immune Dynamics 6 to 18 Months Following Mild
456		Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2): A Case-control
457		Study. Clin Infect Dis, 2023. 76(3): p. e60-e70.
458	17.	Kurahashi, Y., et al., Cross-Neutralizing Breadth and Longevity Against SARS-CoV-2 Variants
459		After Infections. Front Immunol, 2022. 13: p. 773652.
460	18.	Yin, K., et al., Long COVID manifests with T cell dysregulation, inflammation, and an
461		uncoordinated adaptive immune response to SARS-CoV-2. bioRxiv, 2023.
462	19.	Gruell, H., et al., Antibody-mediated neutralization of SARS-CoV-2. Immunity, 2022. 55(6): p.
463		925-944.
464	20.	Peluso, M.J., et al., Long-term SARS-CoV-2-specific immune and inflammatory responses in
465		individuals recovering from COVID-19 with and without post-acute symptoms. Cell Rep, 2021.
466		36(6): p. 109518.
467	21.	Peluso, M.J., et al., SARS-CoV-2 antibody magnitude and detectability are driven by disease
468		severity, timing, and assay. Sci Adv, 2021. 7(31).
469	22.	Garcia-Abellan, J., et al., Antibody Response to SARS-CoV-2 is Associated with Long-term
470		Clinical Outcome in Patients with COVID-19: a Longitudinal Study. J Clin Immunol, 2021. 41(7):
471		p. 1490-1501.
472	23.	Herman, J.D., et al., Impact of cross-coronavirus immunity in post-acute sequelae of COVID-19.
473		medRxiv, 2022.
474	24.	Sullivan, D.J., et al., Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in
475		different vaccinated and unvaccinated convalescent plasma sources. Nat Commun, 2022.
476		13(1): p. 6478.
477	25.	Linderman, S.L., et al., Neutralizing antibody responses in patients hospitalized with SARS-
478		CoV-2 Delta or Omicron infection. J Clin Invest, 2022. 132(23).
479	26.	Odak, I., et al., Longitudinal Tracking of Immune Responses in COVID-19 Convalescents
480		Reveals Absence of Neutralization Activity Against Omicron and Staggered Impairment to Other
481		SARS-CoV-2 Variants of Concern. Front Immunol, 2022. 13: p. 863039.
482	27.	Schuh, A.J., et al., SARS-CoV-2 Convalescent Sera Binding and Neutralizing Antibody
483		Concentrations Compared with COVID-19 Vaccine Efficacy Estimates against Symptomatic
484		Infection. Microbiol Spectr, 2022. 10(4): p. e0124722.
485	28.	Fong, Y., et al., Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy

clinical trial. Nat Commun, 2023. 14(1): p. 331. 486

22

- 487 29. Huang, Y., et al., Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays
 488 for COVID-19 vaccine evaluation. Sci Rep, 2021. 11(1): p. 23921.
- 489 30. Kurhade, C., et al., Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1
 490 by parental mRNA vaccine or a BA.5 bivalent booster. Nat Med, 2023. 29(2): p. 344-347.
- 491 31. Mi, D., J. Hu, and Z. Qian, A Lentiviral Pseudotype System to Characterize SARS-CoV-2
 492 Glycoprotein. Methods Mol Biol, 2023. 2610: p. 187-199.
- 493 32. Hyseni, I., et al., Characterisation of SARS-CoV-2 Lentiviral Pseudotypes and Correlation
 494 between Pseudotype-Based Neutralisation Assays and Live Virus-Based Micro Neutralisation
 495 Assays. Viruses, 2020. 12(9).
- 496 33. Liu, K.T., et al., Overview of Neutralization Assays and International Standard for Detecting
 497 SARS-CoV-2 Neutralizing Antibody. Viruses, 2022. 14(7).
- 498

500 SUPPLEMENTARY MATERIALS







Supplementary Figure 1. Correlation Matrix of Neutralization ID50s For SARS-CoV-2 variants
 tested. Data across all time points are shown in the matrices. R and P values from non-parametric
 Spearman rank correlation analyses.





Supplementary Figure 2. Longitudinal analysis of antibody neutralization by clinical factors and SARS-

CoV-2 variant. Mixed-linear regression model with two covariates (body mass index ad autoimmune disease history) for different variants: SARS-CoV-2, B.1.617.2, B.1.1.529 and BA.4/5. P-values denote if a significant difference was observed for change in antibody neutralization over time (Change over time), between subgroup (Phenotype, e.g., BMI \geq 30), and difference in change over time by subgroup (Change over time by phenotype).

Shaded region represents 95% confidence intervals around the median line.

25



527 528

529 Supplementary Figure 3. Association between SARS-CoV-2 neutralization, hospitalization during acute 530 infection and demographic factors and the odds of experiencing fatigue or cardiopulmonary symptoms 531 approximately four months following acute COVID-19. The top panel shows odds ratios (points) and 95% 532 confidence intervals (bars) for each variable included in logistic regression models using continuous neutralization 533 ID50 values for assays using the original and Omicron BA.5 pseudoviruses (A). The bottom panel shows odds 534 ratios and 95% confidence intervals of developing PASC or specific PASC phenotypes for logistic regression 535 models incorporating a binary variable indicating if a sample had a neutralization ID50 in the top 15% of the 536 cohort to either original SARS-CoV02 or Omicron BA.5 pseudoviruses (B). *P<0.05, **P<0.01, ***P<0.001 from 537 covariate adjusted logistic regression.

- 538
- 539





543 Supplementary Figure 4. Association between SARS-CoV-2 neutralization, hospitalization during acute 544 infection and demographic factors and the odds of experiencing fatigue or cardiopulmonary symptoms 545 approximately four months following acute COVID-19. The top panel shows odds ratios (points) and 95% 546 confidence intervals (bars) for each variable included in logistic regression using continuous neutralization ID50 547 values for assays using the original and Omicron BA.5 pseudoviruses in the same model (A). The bottom panel 548 shows odds ratios and 95% confidence intervals of developing PASC or specific PASC phenotypes for logistic 549 regression incorporating a binary variable indicating if a sample had a neutralization ID50 in the top 15% of the 550 cohort to the original SARS-CoV02 and Omicron BA.5 pseudoviruses (B). *P<0.05, **P<0.01, ***P<0.001 from 551 covariate adjusted logistic regression.

552